Automatic Web Traffic Generator


US   France   Germany   Spain   Netherlands  

Study Of Varlitinib For Firstline Gastric Cancer Treatment Misses Primary Endpoint | AutoTraffic

ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer

In the recently completed study, varlitinib did not meet the primary endpoint of significant reductions in tumour size after 12 weeks of treatment ... ASLAN Pharmaceuticals, said: “First-line gastric ... read more

ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study

ASLAN Pharmaceuticals Limited (ASLN - Free Report) announced that a phase II study, evaluating its pipeline candidate — varlitinib — for the treatment of first-line gastric cancer, failed to meet the ... read more

ASLAN Pharma completes enrollment in mid-stage study of varlitinib in gastric cancer

ASLAN Pharmaceuticals (NASDAQ:ASLN) completes the enrollment of 52 subjects in the first part of its Phase 2/3 clinical trial evaluating pan-HER inhibitor varlitinib, in combination with chemo, for th... read more

ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer Taiwan Stock Exchange:6497.TWO

In the recently completed study, varlitinib did not meet the primary endpoint of significant reductions in tumour size after 12 weeks of treatment ... ASLAN Pharmaceuticals, said: 'First-line gastric ... read more

ASLAN Pharmaceuticals Completes Recruitment for Global Phase 2 Study for Varlitinib in First Line Gastric Cancer

Dr Bertil Lindmark, Chief Medical Officer, ASLAN Pharmaceuticals, said: “We are pleased to complete the patient recruitment for the first part of this important global phase 2/3 study for varlitinib i... read more

Merck's Keytruda Misses Primary End Point for Gastric Cancer

Merck MRK announced disappointing results from a pivotal phase III KEYNOTE-061 study, evaluating its anti-PD-1 therapy, Keytruda (pembrolizumab), as a second-line treatment for patients with advanced ... read more

ASLAN Pharma's varlitinib flunks mid-stage gastric cancer study

A Phase 2 clinical trial evaluating ASLAN Pharmaceuticals' (NASDAQ:ASLN) varlitinib in patients with HER1/HER2-positive advanced/metastatic gastric cancer failed to achieve the primary endpoint. Speci... read more
Subscribe to RSS Feed
Popular RSS Feeds: webhosting bukkit server download culinary arts miss dynamix buy loose diamonds paperback swap cater to you electricity rates blood assurance macarroni testprepreview skyrim oghma infinium emergency plumber university of sydney library car accident lawyers kelley o hara john winston cheapest house insurance wabora toronto jake plummer brown mountain lights school for field studies

Buy AutoTrafficRSS script now for only $27!

We will send the script to your PayPal email within few hours,
Please add FullContentRSS@gmail.com to your email contact.



Auto Traffic generator Powered by. Full RSS Feed | Article Generator | Contact Us